Browse Articles

Filter By:

  • The three-piece inflatable penile prosthesis offers an excellent treatment option for some men with erectile dysfunction, but implant surgery is not without surgical risks and can carry additional cosmetic and psychosocial consequences in poorly selected and consented individuals. In this Consensus Statement, an international group of key opinion leaders and high-volume prosthetic surgeons review the current guidelines and clinical evidence and present their expert consensus regarding patient selection, technique and complications of inflatable penile prosthesis surgery.

    • Eric Chung
    • Carlo Bettocchi
    • Gerald Brock
    Consensus Statement
  • The BIONIKK trial is the first prospective biomarker-driven randomized trial in metastatic clear cell renal cell carcinoma. This trial demonstrates the feasibility of using a transcriptomic biomarker that reflects intrinsic disease biology to optimize treatment efficacy and shows that all patients might not require combination treatment.

    • Eduard Roussel
    • Benoit Beuselinck
    • Maarten Albersen
    News & Views
  • Estimation of post-surgery future glomerular filtration rate (fGFR) is crucial for the oncological management of patients with renal cell carcinoma or urinary tract urothelial carcinoma. A new and simple formula for calculating fGFR has been published and should be included in future guidelines for personalized treatment of patients to guide decisions on surgery, systemic therapies and optimal sequence of treatment.

    • Federico Ferraris
    • Jay D. Raman
    • Jose Rozanec
    Comment
  • The highest risk of death from prostate cancer is associated with increased waist circumference, increased blood pressure, hypertension, type 2 diabetes and obesity; thus, therapies that can reduce blood glucose levels have the potential to improve patient outcomes. The therapeutic benefits of low-carbohydrate and fasting-mimicking diets in patients with prostate cancer have been investigated in two recent studies.

    • Thomas N. Seyfried
    News & Views
  • Standard-of-care management of renal cell carcinoma (RCC) relies on surgery for low-risk localized disease and systemic treatment for poor-prognosis metastatic tumours, but patients with high-risk localized tumours and with metastatic disease that has a good-to-intermediate prognosis are in a grey area for treatment. In this Review, the authors provide a comprehensive overview of the current knowledge on surgery and systemic treatment in the management of metastatic and localized RCC.

    • Alexandre Ingels
    • Riccardo Campi
    • Alexandre de la Taille
    Review Article
  • Reliable information about sexual and reproductive health and service access during coronavirus disease 2019 (COVID-19) are essential. The International Sexual Health and Reproductive Health (I-SHARE) study is led by a multi-country consortium that adopts an open science approach to achieve this goal. Future work will be needed to assess changes in sexual and reproductive health during the lifting of COVID-19 restrictions.

    • Rayner K. J. Tan
    • Kristien Michielsen
    • Joseph D. Tucker
    Comment
  • The sixth edition of the WHO (World Health Organization) semen analysis manual has been released 10 years after the previous edition and includes important updates. In this Perspective article, a comprehensive overview and discussion of the newly released WHO manual are provided. Limitations of routine semen analysis-based infertility assessment and potential solutions to improve male infertility work-up are also discussed.

    • Sandro C. Esteves
    Perspective
  • Limited information exists regarding the effects of prostate cancer therapies on sexual health outcomes in sexual and gender minority patients. As clinicians, scientists and advocates, understanding these outcomes is imperative in order to enable personalized clinical decision-making and to create a more equitable health system.

    • Daniel R. Dickstein
    • Deborah C. Marshall
    Comment
  • Patients with prostate cancer from sexual minority groups experience considerably worse quality of life following prostate cancer treatment than heterosexual patients. Improved inclusivity as well as cultural humility training at the physician, institution and system levels are warranted to address inequalities in quality-of-life outcomes.

    • David J. Benjamin
    • Arash Rezazadeh
    Comment
  • Since calcium/calmodulin-dependent kinase kinase 2 (CAMKK2) was identified as an androgen-receptor-regulated gene, important functional roles of CAMKK2 in prostate cancer progression have been shown in preclinical models. In this Perspective, the authors present evidence supporting an oncogenic role of CAMKK2, and also discuss mechanisms of regulation and emerging non-cell-autonomous roles of CAMKK2. Moreover, the potential use of CAMKK2 as a biomarker and/or therapeutic target in prostate cancer is discussed.

    • Thomas L. Pulliam
    • Pavithr Goli
    • Daniel E. Frigo
    Perspective
  • In this Review, Russo and Giri describe and discuss germline testing criteria, genetic testing strategies, genetically informed screening, precision management, delivery of genetic counselling or alternative genetic services and special considerations for men with prostate cancer.

    • Jessica Russo
    • Veda N. Giri
    Review Article
  • In this Review, the authors describe our current knowledge of the consequences of SARS-CoV-2 infection on the urogenital system, discussing urological symptoms and damage to organs of the genitourinary tract induced by COVID-19 infection. Moreover, the effects of COVID-19 on male fertility and sexual health are discussed.

    • Benedikt Ebner
    • Yannic Volz
    • Giuseppe Magistro
    Review Article